Biotech Values

[genisi]

None of those cases are similar to the Momenta vs. Teva case and I certainly don't think that Momenta's IP is worthless, rather I wanted to show how the courts increasingly have expanded the scope of the safe harbor provision. Patented research tools may well fall outside the safe harbor exemption.